Positive Results in Mouse Model for Experimental Drug Treating Liver Scarring Associated With Nonalcoholic Steatohepatitis (NASH)
Alexas_Fotos / Pixabay

Positive Results in Mouse Model for Experimental Drug Treating Liver Scarring Associated With Nonalcoholic Steatohepatitis (NASH)

According to a story from globenewswire.com, the biopharmaceutical company ContraVir Pharmaceuticals, Inc. has recently announced that its experimental drug CRV431 was able to successfully decrease scarring of the liver in…

Continue Reading Positive Results in Mouse Model for Experimental Drug Treating Liver Scarring Associated With Nonalcoholic Steatohepatitis (NASH)
Retired Professor With Multiple System Atrophy Hopes for a Medically Assisted Death
mamamayerle / Pixabay

Retired Professor With Multiple System Atrophy Hopes for a Medically Assisted Death

According to a story from Southwest Journal, retired professor Karen Warren was first diagnosed in 2015 with multiple system atrophy, a lethal neurodegenerative disorder. The disease carries an unpleasant group…

Continue Reading Retired Professor With Multiple System Atrophy Hopes for a Medically Assisted Death
Study Suggests Female Cancer Patients Have Better Outcomes After Treatment, Experience Worse Side Effects
DarkoStojanovic / Pixabay

Study Suggests Female Cancer Patients Have Better Outcomes After Treatment, Experience Worse Side Effects

According to a publication from EurekAlert, a recent study helmed by the Royal Marsden NHS Foundation Trust suggests that female cancer patients tend to live slightly longer following treatment than…

Continue Reading Study Suggests Female Cancer Patients Have Better Outcomes After Treatment, Experience Worse Side Effects
Duchenne Muscular Dystrophy and The Heart: Five Facts You Should Know
3dman_eu / Pixabay

Duchenne Muscular Dystrophy and The Heart: Five Facts You Should Know

According to a story from blog.cincinnatichildrens.org, a diagnosis of Duchenne muscular dystrophy is always an alarming piece of news; learning that your child has a progressive muscle atrophy disorder that…

Continue Reading Duchenne Muscular Dystrophy and The Heart: Five Facts You Should Know

Experimental Hemophilia A Drug Loses Effectiveness Over Time, Efficacy Questionable After 8th Year

According to a publication from Reuters, based on early clinical data, American biotechnology company BioMarin Pharmaceuticals believes that a single injection of its experimental hemophilia A drug could relieve symptoms…

Continue Reading Experimental Hemophilia A Drug Loses Effectiveness Over Time, Efficacy Questionable After 8th Year

Legal and Ethical Questions: What is Pharma’s Obligation to Pursue Development of a Promising but Non-Profitable Drug?

  Dr. Craig Klugman, a bioethics professor at DePaul University, expresses his opinion in this recent article in Columbia University’s Bioethics.com. Dr. Klugman begins with a discussion of Pfizer’s biological drug,…

Continue Reading Legal and Ethical Questions: What is Pharma’s Obligation to Pursue Development of a Promising but Non-Profitable Drug?

Phase 1/2 Trial for an Experimental Phenylketonuria Gene Therapy Has Begun Enrollment

According to a story from globenewswire.com, the genetic medicines company Homology Medicines, Inc. has recently announced that it has opened enrollment for its phase 1/2 clinical trial. This clinical trial…

Continue Reading Phase 1/2 Trial for an Experimental Phenylketonuria Gene Therapy Has Begun Enrollment
ICYMI: First Patient is Dosed in Phase 2 Friedreich’s Ataxia Trial
HeungSoon / Pixabay

ICYMI: First Patient is Dosed in Phase 2 Friedreich’s Ataxia Trial

According to a story from Ysios Capital, the biotechnology company Minoryx Therapeutics recently announced that the first patient has been dosed in the company's phase 2 clinical trial. This trial…

Continue Reading ICYMI: First Patient is Dosed in Phase 2 Friedreich’s Ataxia Trial
Immunotherapy Elicits Positive Response in Acute Myeloid Leukemia and Myelodysplastic Syndromes Patients
source: pixabay.com

Immunotherapy Elicits Positive Response in Acute Myeloid Leukemia and Myelodysplastic Syndromes Patients

According to a story from mdmag.com, a recent study that was presented at the 2019 meeting of the American Society of Clinical Oncology has demonstrated the potential of a two…

Continue Reading Immunotherapy Elicits Positive Response in Acute Myeloid Leukemia and Myelodysplastic Syndromes Patients
Potential Treatment for Neurofibromatosis Type 1 Earns Fast Track Designation
Free-Photos / Pixabay

Potential Treatment for Neurofibromatosis Type 1 Earns Fast Track Designation

According to a story from Acrofan, the biopharmaceutical company SpringWorks Therapeutics, Inc. has recently announced the that company's experimental product candidate PD-0325901 has earned Fast Track designation from the US…

Continue Reading Potential Treatment for Neurofibromatosis Type 1 Earns Fast Track Designation
Orphazyme Preps to File European Marketing Application for Experimental Niemann-Pick disease Type C Drug
stevepb / Pixabay

Orphazyme Preps to File European Marketing Application for Experimental Niemann-Pick disease Type C Drug

According to a press release from Danish biopharmaceutical company Orphazyme, the Company intents to proceed with a marketing authorisation application (MAA) for its experimental Niemann-Pick disease type C treatment arimoclomol.…

Continue Reading Orphazyme Preps to File European Marketing Application for Experimental Niemann-Pick disease Type C Drug